Physician profile
Stephen Witanowski
NPI 1003040726
$1,072.84
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $265 · 2021: $18.58.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $221.08 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $207.55 | 2019-2020 | |
| Lilly USA, LLC | $90.48 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.48 | 2019-2020 | |
| Amgen INC. | $75.66 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $67.62 | 2019-2020 | |
| Amarin Pharma, INC. | $59.91 | 2019-2020 | |
| Allergan, INC. | $49.79 | 2019 | |
| Glaxosmithkline, LLC. | $28.79 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.28 | 2019-2020 | |
| Mannkind Corporation | $24.07 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $22.43 | 2019 | |
| Dexcom, INC. | $18.58 | 2021 | |
| Eisai INC. | $17.87 | 2020 | |
| Pfizer INC. | $16.49 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $16.47 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.78 | 2019 | |
| Hikma Pharmaceuticals USA | $11.83 | 2020 | |
| Astellas Pharma US INC | $11.78 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Witanowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.